Issue Archive
October 2013 | Volume 12 | Issue 10
Editorials
Psoriasis and Leprosy are Teaching Us T-Cell Plasticity
MicroRNA-29 and an Integrated Understanding of Atrial Fibrillation
The Use of Photodynamic Therapy as Chemoprevention for the Treatment of Actinic Keratoses and Reduction in the Number of Non-Melanoma Skin Cancers
Possible Drug-Drug Interaction Between Adalimumab and Duloxetine and/or Pregabalin in a Psoriasis Patient
Original Articles
Adherence to Ustekinumab in Psoriasis Patients
BACKGROUND: Adherence to the treatment of psoriasis is poor and effects treatment outcomes. Literature on adherence to biologic therapy for the treatment of psoriasis is limited and difficult to measu...
Read MorePsoriasis Treatments by Payment Type in the US Outpatient Office Setting
BACKGROUND: Many factors, including patients' methods of payment, may influence psoriasis treatment decisions.
OBJECTIVE: To characterize psoriasis treatments by patients' types of payment in t...
Read MoreCombination Use of Ustekinumab With Other Systemic Therapies: A Retrospective Study in a Tertiary Referral Center
BACKGROUND: Patients with moderate to severe psoriasis may not respond adequately to single systemic agent and may require combination systemic therapy.
OBJECTIVE: To evaluate the prevalence, i...
Read MoreNutritional Clinical Studies in Dermatology
BACKGROUND & AIMS: Nutrition has long been associated with skin health, beauty, integrity and aging through multiple pathways and cofactors implicated in skin biology. The onset and clinical course of...
Read MoreImmune Response to Pneumococcus and Tetanus Toxoid in Patients With Moderate-to-Severe Psoriasis Following Long-Term Ustekinumab Use
BACKGROUND: Little is known about the impact of long-term use of immunosuppressive agents on immune response.
OBJECTIVES: Assess the impact of continuous maintenance ustekinumab treatment on pa...
Read MoreCurcumin: A Novel Treatment for Skin-Related Disorders
Curcumin, or diferuloylmethane, is a crystalline compound which gives the East Asian spice turmeric its bright yellow color. The medicinal properties of this spice have been referenced in numerous cou...
Read MorePurpura and Fillers: A Review of Pre-Procedural, Intra-Procedural, and Post-Procedural Considerations
Injectable aesthetic fillers are associated with the common and expected side effect of purpura or bruising. There are pre-procedural, intra-procedural and post-procedural considerations that can pote...
Read MorePimecrolimus Cream and Tacrolimus Ointment in the Treatment of Atopic Dermatitis: A Pilot Study on Patient Preference
Background: Pimecrolimus cream 1% is approved for mild to moderate atopic dermatitis in children older than two years of age and adults. Tacrolimus ointment 0.03% is approved for moderate to severe at...
Read MoreEfficacy of Combination of Glycolic Acid Peeling With Topical Regimen in Treatment of Melasma
BACKGROUND: Various treatment modalities are available for management of melasma, ranging from topical and oral to chemical peeling, but none is promising alone. Very few studies are available regardi...
Read MoreValrubicin Activates PKCα in Keratinocytes: A Conceivable Mode of Action in Treating Hyper-Proliferative Skin Diseases
BACKGROUND: Valrubicin is a semisynthetic anthracycline developed as an anti-cancer drug able to ameliorate psoriasis and non-melanoma skin cancer (NMSC) by topical application in animal models. Valru...
Read MoreFocal Acne Scar Treatment (FAST), a New Approach to Atrophic Acne Scars: A Case Series
BACKGROUND: Acne scars are a common concern in dermatology. Fractional CO2 laser resurfacing is a recent addition in our armamentarium of treatment options for acne scars and has been shown to be an e...
Read MoreUnderstanding BCC Pathogenesis: Treatment Advancements and Challenges
Features
Resident Rounds. Program Spotlight: Weill Cornell Medical College
Resident Rounds is a section of the JDD dedicated to highlighting various dermatology departments with residency training programs. Resident Rounds includes three sections: (1) a program spotlight, h...
Read MoreNews, Views and Reviews
Pipeline Previews
Clinical Trial Review
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select...
Read More
Case Reports
Etanercept Urticaria in a Patient With Psoriasis Desensitized Using a New Method
Desensitization is the process of rendering an individual who is allergic to a food or chemical substance like a drug able to tolerate the agent. This is usually accomplished by exposing the patient t...
Read MoreMinimizing Skin Cancer Surgical Scars Using Ablative Fractional Er:Yag Laser Treatment
BACKGROUND and OBJECTIVE: Scars from skin cancer surgery on the face can be quite prominent and not easily obscured by makeup. This report evaluates the use of an ablative fractional Er:YAG laser devi...
Read MoreA Novel Anti-Inflammatory in Treatment of Acne Vulgaris: The Pseudopterosins
The pseudopterosins derived from the marine gorgonian octocoral, P. elisabethae are novel biologically active compounds increasingly recognized for their anti-inflammatory, analgesic, and wound healin...
Read MorePost-Filler Vascular Occlusion: A Cautionary Tale and Emphasis for Early Intervention
We report a case of a 36-year-old female who experienced significant vascular occlusion after injection with hyaluronic acid into the nasolabial folds. The patient experienced immediate pain after the...
Read More
Supplements
Introduction
Treatment of Margin Positive Basal Cell Carcinoma With Vismodegib: Case Report and Consideration of Treatment Options and Their Implications
Historically, basal cell carcinomas (BCCs) that are neither surgically resectable nor candidates for radiation therapy have had few treatment options. The hedgehog pathway inhibitor, vismodegib, repre...
Read MoreThe Impact of Inoperable Advanced Basal Cell Carcinoma: the Economic, Physical, and Psychological Burden of the Disease
The development of vismodegib and its recent approval by the United States Food and Drug Administration for use in patients with locally advanced or metastatic basal cell carcinoma (BCC) carries with ...
Read MoreVismodegib: A Hedgehog Pathway Inhibitor for Locally Advanced and Metastatic Basal Cell Carcinomas
Basal cell carcinomas (BCCs) are the most common cancer in the United States, and the overwhelming majority of BCCs are the result of hedgehog pathway activation. While locally advanced and metastatic...
Read MoreAdvanced Basal Cell Carcinoma: Therapeutic Options and Considerations for Patient Care
Vismodegib Ushers in New Era for the Treatment of Basal Cell Carcinoma
Approximately 2.8 million basal cell carcinomas (BCCs) occur in the United States each year, accounting for 80% of a...
Read More
